Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease.

BACKGROUND & AIMS Childhood-onset inflammatory bowel disease (IBD) might be etiologically different from adult-onset IBD. We analyzed disease phenotypes and progression of childhood-onset disease and compared them with characteristics of adult-onset disease in patients in Scotland. METHODS Anatomic locations and behaviors were assessed in 416 patients with childhood-onset (276 Crohn's disease [CD], 99 ulcerative colitis [UC], 41 IBD type unclassified [IBDU] diagnosed before seventeenth birthday) and 1297 patients with adult-onset (596 CD, 701 UC) IBD using the Montreal classification. RESULTS At the time of diagnosis in children, CD involved small bowel and colon (L3) in 51% (138/273), colon (L2) in 36%, and ileum (L1) in 6%; the upper gastrointestinal (GI) tract (L4) was also affected in 51%. In 39%, the anatomic extent increased within 2 years. Behavioral characteristics progressed; 24% of children developed stricturing or penetrating complications within 4 years (vs 9% at diagnosis; P < .0001; odds ratio [OR], 3.32; 95% confidence interval [CI], 1.86-5.92). Compared with adults, childhood-onset disease was characterized by a "panenteric" phenotype (ileocolonic plus upper GI [L3+L4]; 43% vs 3%; P < .0001; OR, 23.36; 95% CI, 13.45-40.59) with less isolated ileal (L1; 2% vs 31%; P < .0001; OR, 0.06; 95% CI, 0.03-0.12) or colonic disease (L2; 15% vs 36%; P < .0001; OR, 0.31; 95% CI, 0.21-0.46). UC was extensive in 82% of the children at diagnosis, versus 48% of adults (P < .0001; OR, 5.08; 95% CI, 2.73-9.45); 46% of the children progressed to develop extensive colitis during follow-up. Forty-six percent of children with CD and 35% with UC required immunomodulatory therapy within 12 months of diagnosis. The median time to first surgery was longer in childhood-onset than adult-onset patients with CD (13.7 vs 7.8 years; P < .001); the reverse was true for UC. CONCLUSIONS Childhood-onset IBD is characterized by extensive intestinal involvement and rapid early progression.

[1]  R. Hoffmann,et al.  Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. , 2003, The Journal of pediatrics.

[2]  M. Vatn,et al.  Clinical course in Crohn's disease: Results of a five-year population-based follow-up study (the IBSEN study) , 2007, Scandinavian journal of gastroenterology.

[3]  A. Griffiths.  Specificities of inflammatory bowel disease in childhood. , 2004, Best practice & research. Clinical gastroenterology.

[4]  A. Griffiths,et al.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.

[5]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.

[6]  Geraint T. Williams,et al.  The incidence of Crohn’s disease in Cardiff over the last 75 years: an update for 1996–2005 , 2007, Alimentary pharmacology & therapeutics.

[7]  B. Sandhu,et al.  Presenting features of inflammatory bowel disease in Great Britain and Ireland , 2003, Archives of disease in childhood.

[8]  Athos Bousvaros,et al.  The Crohn’s and Colitis Foundation of America , 2018, The Grants Register 2019.

[9]  J. Markowitz,et al.  A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.

[10]  D. Jewell,et al.  A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.

[11]  J. Hugot,et al.  Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. , 2005, Journal of pediatric gastroenterology and nutrition.

[12]  J. Satsangi,et al.  Crohn’s disease or Crohn’s diseases? , 2003, Gut.

[13]  A. Griffiths,et al.  Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease , 2007, The American Journal of Gastroenterology.

[14]  J. Belaiche,et al.  Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease , 2001, Gut.

[15]  A. Latiano,et al.  Polymorphisms of Tumor Necrosis Factor-α but Not MDR1 Influence Response to Medical Therapy in Pediatric-Onset Inflammatory Bowel Disease , 2007, Journal of pediatric gastroenterology and nutrition.

[16]  R. Baker,et al.  Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England , 2003, European journal of gastroenterology & hepatology.

[17]  Mark Avigan,et al.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. , 2007, Journal of pediatric gastroenterology and nutrition.

[18]  N. LeLeiko,et al.  Distinct Phenotype of Early Childhood Inflammatory Bowel Disease , 2006, Journal of clinical gastroenterology.

[19]  J. Witte,et al.  Disease outcome in inflammatory bowel disease: mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). , 2000, Scandinavian journal of gastroenterology.

[20]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[21]  R. Baldassano,et al.  Inflammatory bowel disease in children 5 years of age and younger , 2002, American Journal of Gastroenterology.

[22]  Joseph T. Glessner,et al.  Association of the T300A non-synonymous variant of the ATG16L1 gene with susceptibility to paediatric Crohn’s disease , 2007, Gut.

[23]  H. Drummond,et al.  Disease Location, Anti-Saccharomyces cerevisiae Antibody, and NOD2/CARD15 Genotype Influence the Progression of Disease Behavior in Crohn’s Disease , 2004, Inflammatory bowel diseases.

[24]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[25]  J. Belaiche,et al.  Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype , 2003, Gut.

[26]  R. Baldassano,et al.  Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. , 2005, The Journal of pediatrics.

[27]  M. Vatn,et al.  Ulcerative colitis and clinical course: Results of a 5‐year population‐based follow‐up study (the IBSEN study) , 2006, Inflammatory bowel diseases.

[28]  H. Drummond,et al.  Increasing incidence of both juvenile-onset Crohn's disease and ulcerative colitis in Scotland , 2001, European journal of gastroenterology & hepatology.

[29]  H. Drummond,et al.  1043 The Efficacy of Corticosteroid Therapy: Analysis of 10-Year Inflammatory Bowel Disease Inception Cohort (1998-2007) , 2008 .

[30]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[31]  B. Koletzko,et al.  ESPGHAN and ESPEN Guidelines Paediatric Parenteral Nutrition - Annex: List of Products , 2005, Journal of pediatric gastroenterology and nutrition.

[32]  Stefan Schreiber,et al.  Diagnostics of inflammatory bowel disease. , 2007, Gastroenterology.

[33]  R. Baldassano,et al.  Gender Differences in Presentation and Course of Disease in Pediatric Patients With Crohn Disease , 2007, Pediatrics.